Regeneron Pharmaceuticals, Inc. with price, financials, news flow, and insider context in one page.
Regeneron Pharmaceuticals, Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where REGN sits inside Healthcare and Biotechnology, and the key financial markers that matter before moving into a fuller research workflow.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
This page is structured for research context, not a trade call. It gives you a clean read on where REGN sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 3.61B | 727.2M | 799.4M |
| Q4 2025 | 3.88B | 844.6M | 880M |
| Q3 2025 | 3.75B | 1.46B | 1.37B |
| Q2 2025 | 3.68B | 1.39B | 737.6M |
The NASDAQ index continues to power to new record highs, with the latest all-time peak reaching 26,474.18. The index is currently trading at 26,454.91, up 366 points or 1.41% on the day.Looking at ...
Official CPI masks double-digit spikes in healthcare, insurance and energy. Meanwhile, an outdated strategy quietly drains your portfolio.
A public stock page should answer the first research questions before asking for a signup.
This REGN page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.